Cargando…
Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and en...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222238/ https://www.ncbi.nlm.nih.gov/pubmed/30498512 http://dx.doi.org/10.1155/2018/8653489 |
_version_ | 1783369161735405568 |
---|---|
author | Matsushita, Maiko Kawaguchi, Mai |
author_facet | Matsushita, Maiko Kawaguchi, Mai |
author_sort | Matsushita, Maiko |
collection | PubMed |
description | Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients. |
format | Online Article Text |
id | pubmed-6222238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-62222382018-11-29 Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy Matsushita, Maiko Kawaguchi, Mai J Oncol Review Article Recent advances in cancer immunotherapy, including immune checkpoint inhibitors or adoptive T cell therapies, have contributed to better outcomes in cancer patients. However, there are still many cancers with no cure. Therefore, combinations of several treatment strategies are being explored, and enhancing anticancer immunity will play an important role to combat the disease. There have been several reports on the immune-modulatory effects of commonly used drugs, namely, statin, metformin, and angiotensin receptor blockers (ARBs), which suggest that these drugs could enhance immunity against cancer cells. Other anticancer drugs, such as anthracyclines, thalidomides, lenalidomides, and hypomethylating drugs, could also strengthen the immune system to attack cancer cells at a relatively low dose. Hence, these drugs might contribute to better outcomes in cancer patients. Hindawi 2018-10-25 /pmc/articles/PMC6222238/ /pubmed/30498512 http://dx.doi.org/10.1155/2018/8653489 Text en Copyright © 2018 Maiko Matsushita and Mai Kawaguchi. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Matsushita, Maiko Kawaguchi, Mai Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title | Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title_full | Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title_fullStr | Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title_full_unstemmed | Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title_short | Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy |
title_sort | immunomodulatory effects of drugs for effective cancer immunotherapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222238/ https://www.ncbi.nlm.nih.gov/pubmed/30498512 http://dx.doi.org/10.1155/2018/8653489 |
work_keys_str_mv | AT matsushitamaiko immunomodulatoryeffectsofdrugsforeffectivecancerimmunotherapy AT kawaguchimai immunomodulatoryeffectsofdrugsforeffectivecancerimmunotherapy |